flutamide and Hyperlipemia studies

Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Research Excerpts

Excerpt	Relevance	Reference
"The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy."	9.10	Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003)
" Flutamide, a nonsteroidal antiandrogen, is known to be effective in reducing hirsutism in patients with ovarian hyperandrogenism."	9.09	Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N, 2000)
"Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0."	5.30	The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Duleba, AJ; Mitrakou, A; Raptis, S; Tolis, G, 1998)
"The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy."	5.10	Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003)
" Flutamide, a nonsteroidal antiandrogen, is known to be effective in reducing hirsutism in patients with ovarian hyperandrogenism."	5.09	Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. ( de Zegher, F; Ibáñez, L; Marcos, MV; Potau, N, 2000)
"We hypothesized that dyslipidemia and anovulation in nonobese women with polycystic ovary syndrome are essentially secondary to the concerted effects of hyperandrogenism and insulin resistance."	2.70	Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. ( De Zegher, F; Dunger, DB; Ferrer, A; Ibáñez, L; Ong, K; Valls, C, 2002)
"Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0."	1.30	The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Duleba, AJ; Mitrakou, A; Raptis, S; Tolis, G, 1998)

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Disposition Index

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Ibáñez, L	3
de Zegher, F	3
Diamanti-Kandarakis, E	1
Mitrakou, A	1
Raptis, S	1
Tolis, G	1
Duleba, AJ	1
Potau, N	1
Marcos, MV	1
Valls, C	1
Ferrer, A	1
Ong, K	1
Dunger, DB	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Metabolic Syndrome in PCOS: Precursors and Interventions[NCT00442689]		97 participants (Actual)	Interventional	2006-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months

Change in Fat Percentage as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan Over the Study Period

Intervention	min^-1 (Mean)
Oral Contraceptive - 1	1653
Flutamide - 2	194
Placebo - 3	-184

Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months

Change in High-density Lipoprotein (HDL) Levels During Study Period

Intervention	percentage of body mass (Mean)
Oral Contraceptive - 1	0.4
Flutamide - 2	-1.9
Placebo - 3	-1.9

Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months

Change in Low-density Lipoprotein (LDL) Levels Over the Study Period

Intervention	mg/dL (Mean)
Oral Contraceptive - 1	6
Flutamide - 2	-5
Placebo - 3	-2

Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months

Change in Maximal Aerobic Exercise Capacity (VO2 Max) Over the Study Period

Intervention	mg/dL (Mean)
Oral Contraceptive - 1	-6
Flutamide - 2	-9
Placebo - 3	-7

Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months

Change in Resting Energy Expenditure (REE) Over the Study Period

Intervention	L/min (Mean)
Oral Contraceptive - 1	-0.5
Flutamide - 2	-1.6
Placebo - 3	1.1

Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months

Change in Visceral Adipose Tissue (VAT) Volume as Measured by MRI

Intervention	Kcal/day (Mean)
Oral Contraceptive - 1	7
Flutamide - 2	-79
Placebo - 3	-88

Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months

Article	Year
Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. Human reproduction (Oxford, England), 2003, Volume: 18, Issue:1 Topics: Adult; Androgen Antagonists; Cohort Studies; Contraceptives, Oral; Dose-Response Relationship, Drug;	2003
Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. The Journal of clinical endocrinology and metabolism, 2000, Volume: 85, Issue:9 Topics: Adolescent; Androgen Antagonists; Blood Glucose; Female; Flutamide; Glucose Tolerance Test; Hirsutis	2000
Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:6 Topics: Adult; Androgen Antagonists; Anovulation; Drug Combinations; Female; Flutamide; Humans; Hyperandroge	2002

flutamide and Hyperlipemia